Benjamin Blasco1, Didier Leroy1, David A Fidock2,3. 1. Medicines for Malaria Venture, Geneva, Switzerland. 2. Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA. 3. Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
Abstract
The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.
The global adoption of al">artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant al">pan class="Species">Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.
Authors: Juliana Martha Sá; Olivia Twu; Karen Hayton; Sahily Reyes; Michael P Fay; Pascal Ringwald; Thomas E Wellems Journal: Proc Natl Acad Sci U S A Date: 2009-11-02 Impact factor: 11.205
Authors: Michelle Yi-Xiu Lim; Gregory LaMonte; Marcus C S Lee; Christin Reimer; Bee Huat Tan; Victoria Corey; Bianca F Tjahjadi; Adeline Chua; Marie Nachon; René Wintjens; Peter Gedeck; Benoit Malleret; Laurent Renia; Ghislain M C Bonamy; Paul Chi-Lui Ho; Bryan K S Yeung; Eric D Chow; Liting Lim; David A Fidock; Thierry T Diagana; Elizabeth A Winzeler; Pablo Bifani Journal: Nat Microbiol Date: 2016-09-19 Impact factor: 17.745
Authors: Case W McNamara; Marcus Cs Lee; Chek Shik Lim; Siau Hoi Lim; Jason Roland; Oliver Simon; Bryan Ks Yeung; Arnab K Chatterjee; Susan L McCormack; Micah J Manary; Anne-Marie Zeeman; Koen J Dechering; Tr Santha Kumar; Philipp P Henrich; Kerstin Gagaring; Maureen Ibanez; Nobutaka Kato; Kelli L Kuhen; Christoph Fischli; Advait Nagle; Matthias Rottmann; David M Plouffe; Badry Bursulaya; Stephan Meister; Lucia Rameh; Joerg Trappe; Dorothea Haasen; Martijn Timmerman; Robert W Sauerwein; Rossarin Suwanarusk; Bruce Russell; Laurent Renia; Francois Nosten; David C Tully; Clemens Hm Kocken; Richard J Glynne; Christophe Bodenreider; David A Fidock; Thierry T Diagana; Elizabeth A Winzeler Journal: Nature Date: 2013-11-27 Impact factor: 49.962
Authors: Lais Pessanha de Carvalho; Thaisa Lucas Sandri; Edésio José Tenório de Melo; Rolf Fendel; Peter G Kremsner; Benjamin Mordmüller; Jana Held Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191
Authors: Megan R Ansbro; Zina Itkin; Lu Chen; Gergely Zahoranszky-Kohalmi; Chanaki Amaratunga; Olivo Miotto; Tyler Peryea; Charlotte V Hobbs; Seila Suon; Juliana M Sá; Arjen M Dondorp; Rob W van der Pluijm; Thomas E Wellems; Anton Simeonov; Richard T Eastman Journal: ACS Pharmacol Transl Sci Date: 2020-11-02